In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y
- PMID: 36877974
- DOI: 10.7326/J23-0009
In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y
Abstract
EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. 36331190.
Comment on
-
Empagliflozin in Patients with Chronic Kidney Disease.N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical